Cipla share price declined 2 percent after the United States Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI). At 09:29am, Cipla was quoting ...

Cipla: The pharma player has informed the exchanges that its manufacturing facility in Bengaluru's Virgonagar has received a Voluntary Action Indicated status from the USFDA. VA Tech Wabag ...

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...

HYDERABAD/BENGALURU, Jan 28 (Reuters) - Cipla (CIPL.NS), opens new tab, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab ...

Cipla's stock is priced at Rs 1473.75, showing an increase of 1.7% today, with a monthly return of 2.73%. Cipla's shares are currently priced at Rs 1477.55, reflecting a daily increase of 1.96%. The ...

Shares traded at ₹358.05 on the NSE, down 2.09%. Cipla Ltd recorded its consolidated net profit for the quarter ended December 2024 at ₹1,574.59 crore as against ₹1,068.41 crore in the ...

Cipla is currently trading at Rs 1470.55, reflecting a notable increase of 2.35% today, with 1-day returns at 2.03%. Cipla is currently valued at Rs 1466.00, marking a 2.04% rise today. The one-year ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla Q3 Profit Surges 49% to Rs 1,571 Crore Cipla's net profit for Q3 FY25 jumped 49% to Rs 1,571 crore, driven by growth across markets. Revenue rose to Rs 7,073 crore. Read more. Jan 28, 2025 16:23 ...